Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1680 • ACR Convergence 2023
What Trade-offs Are Acceptable to Rheumatoid Arthritis Patients During Treatment Selection?
Rieke Alten¹, Juan carlos Nieto-Gonzalez², Peggy Jacques³, Carlomaurizio Montecucco⁴, Robert Moots⁵, Helga Radner⁶, Sebastian Heidenreich⁷, Chiara Whichello⁷, Nicolas Krucien⁷, Monia Zignani⁸, Harald Vonkeman⁹ and Katrien Van Beneden¹⁰, ¹Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, ²Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Department of Rheumatology and VIB Inflammation Research Center, University Hospital Ghent, Ghent, Belgium, ⁴Division of Rheumatology, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁵Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, ⁶Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁷Patient-centred Research, Evidera Inc., London, United Kingdom, ⁸Medical Affairs, Galapagos GmbH, Basel, Switzerland, ⁹Department of Rheumatology, Medisch Spectrum Twente and University of Twente, Enschede, Netherlands, ¹⁰Medical Safety, Galapagos NV, Mechelen, Belgium
Background/Purpose: Multiple RA therapies are available that differ in attributes such as mode of administration and benefit-risk profile. Challenging trade-offs are made during treatment selection…
Abstract Number: 1735 • ACR Convergence 2023
An Unorthodox HLA-DRhiCD15+ ‘Hybrid’ Population in Rheumatoid Arthritis Characterized Using Spectral Cytometry
Christian Geier¹, Haani Qudsi², Jihad BenGabr¹, Robert Winchester³ and Andras Perl⁴, ¹SUNY Upstate Medical University, Syracuse, NY, ²Norton College of Medicine, SUNY Upstate Medical University, Syracuse, NY, ³Columbia University, New York, NY, ⁴SUNY, Syracuse, NY
Background/Purpose: A variant of HLA-DR confers the strongest genetic risk for rheumatoid arthritis (RA) suggesting that DRhi cells are important in RA. We previously found…
Abstract Number: 1751 • ACR Convergence 2023
Profiling of Anti-PAD IgG and IgA in Patients from the Head-to-head Adalimumab vs Abatacept Rheumatoid Arthritis AMPLE Trial and Matched Healthy Controls
Namit Kumar¹, Xueer Chen², Mary Ann Aure³, Andy Ishii⁴, Laura Martinez-Prat⁵, chelsea Bentow⁴, Jasmine Saini², Michael Mahler⁴ and Laurence Menard², ¹Bristol Myers Squibb, San Diego, CA, ²Bristol Myers Squibb, Princeton, NJ, ³Werfen, Chula Vista, CA, ⁴Werfen, San Diego, CA, ⁵Werfen Autoimmunity, Sant Cugat del Vallès, Spain
Background/Purpose: A hallmark of rheumatoid arthritis (RA) is the presence of anti-citrullinated protein antibodies (ACPA) targeting neoantigens which are generated by a family of enzymes…
Abstract Number: 1767 • ACR Convergence 2023
TNF-α Utilizes the TWEAK/Fn-14 Axis in Human Rheumatoid Arthritis Synovial Fibroblasts to Induce Inflammation
Farheen Sultan Shaikh¹, Anil Singh¹, Paul Panipinto² and Salahuddin Ahmed¹, ¹Washington State University, Spokane, WA, ²Washington State University College of Pharmaceutical Science and Molecular Medicine, Spokane, WA
Background/Purpose: Tumor necrosis factor-alpha (TNF)-α is a proinflammatory cytokine in rheumatoid arthritis that transduces intracellular signal transduction pathways through specific receptors, TNF-R1, and TNF-R2. The…
Abstract Number: 1860 • ACR Convergence 2023
Evaluation of the Receipt of Adequate Pharmacological and Psychological Treatment for Incident Depression and Anxiety in Individuals Living with Inflammatory Arthritis
Alyssa Howren¹, Eric Sayre², J. Antonio Avina-Zubieta³, Joseph Puyat¹, Deborah Da Costa⁴, Hui Xie⁵, Amit Gupta¹ and Mary De Vera¹, ¹University of British Columbia, Vancouver, BC, Canada, ²British Columbia Centre on Substance Use, Vancouver, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴McGill University, Pointe-Claire, QC, Canada, ⁵Simon Fraser University, Richmond, BC, Canada
Background/Purpose: To describe patterns of pharmacological and psychological treatment and evaluate the receipt of minimally adequate treatment for incident depression and anxiety in individuals with…
Abstract Number: 1934 • ACR Convergence 2023
Pooled Safety Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis
Stanley Cohen¹, Shaun Bender², Amy Shaberman³, Richard Vinisko³ and Dorothy McCabe³, ¹University of Texas Southwestern, Dallas, TX, ²Alnylam Pharmaceuticals, Cambridge, MA, ³Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT
Background/Purpose: The VOLTAIRE trials program compared the safety, efficacy, and immunogenicity of biosimilar BI 695501 with adalimumab reference product (RP) for indications including moderate-severe rheumatoid…
Abstract Number: 2105 • ACR Convergence 2023
Cohort-wide Immuno-phenotype Deconvolute Immunological and Clinical Heterogeneity Across Autoimmune Rheumatic Diseases
Hiroaki Tanaka¹, Yukinori Okada², Shingo Nakayamada¹, Yusuke Miyazaki³, Kyuto Sonehara⁴, Shinichi Namba⁵, Suguru Honda⁶, Yuya Shirai⁷, Kenichi Yamamoto⁵, Katsunori Ikari⁸, Masayoshi Harigai⁹, KOSHIRO SONOMOTO¹⁰ and Yoshiya Tanaka¹, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²University of Tokyo / Osaka University / RIKEN, Tokyo, Japan, ³The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kiakyusyu Fukuoka, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵Osaka University, Osaka, Japan, ⁶Tokyo Women's Medical University, Tokyo, Japan, ⁷Osaka University, Suita, Japan, ⁸Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ⁹Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ¹⁰University of Occupational and Environmental Health, Beppu, Japan
Background/Purpose: Autoimmune rheumatic diseases (AIRDs) are systemic but heterogeneous diseases characterized by orchestration of disrupted self-tolerance of immune systems. We face a challenge in characterizing…
Abstract Number: 2121 • ACR Convergence 2023
Clinical Significance of Negative Seroconversion of Anti-CCP and Anti-Mutated Citrullinated Vimentin Antibodies in Patients with Rheumatoid Arthritis
Takao Fujii, Katsunori Tanaka, Ryo Matsumiya, Kayoko Tabata and Shigeru Iwata, Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan
Background/Purpose: Anti-cyclic citrullinated peptide antibody (anti-CCP Ab) positivity is closely associated with bone destruction in rheumatoid arthritis (RA) patients, but the correlation between the Ab…
Abstract Number: 2137 • ACR Convergence 2023
Line of Therapy of Biologics and JAK Inhibitors in RA, PsA and AxSpA: Implications for Design and Uptake of New Drugs and Diagnostics
Jeffrey Curtis¹, Fenglong Xie¹, Yuji Su², Patrick Stewart³ and Amy S. Mudano¹, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham and Illumination Health, Birmingham, AL, ³Illumination Health, Birmingham, AL
Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA) have an increasing array of treatment options available, and new blood-based diagnostic…
Abstract Number: 2153 • ACR Convergence 2023
Effects of One-year Tofacitinib Therapy on Angiogenic Biomarkers in Rheumatoid Arthritis
György Kerekes¹, Monika Czókolyová¹, Attila Hamar¹, Anita Pusztai¹, Gábor Tajti¹, Mónika Katkó¹, Edit Végh¹, Zsófia Pethő¹, Nóra Bodnár¹, Ágnes Horváth¹, Boglárka Soós¹, Szilvia Szamosi¹, Zsolt Hascsi¹, Mariann Harangi¹, Katalin Hodosi¹, György Panyi¹, Tamas Seres², Gabriella Szücs¹ and Zoltán Szekanecz¹, ¹University of Debrecen, Faculty of Medicine, Debrecen, Hungary, ²University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Cardiovascular (CV) morbidity, mortality and perpetuated synovial angiogenesis have been associated with rheumatoid arthritis (RA). In our study we evaluated angiogenic factors in relation…
Abstract Number: 2170 • ACR Convergence 2023
Systemic Glucocorticoids Are Associated with a Time and Dose-dependent Risk of Major Adverse Cardiovascular Event in Patients with Rheumatoid Arthritis: A Population-based Study
Ho SO¹, Tommy LAM², Huan MENG³, Steven LAM³ and Lai-Shan Tam⁴, ¹The Chinese University of Hong Kong, Hong Kong, China, ²Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong, Hong Kong, ³The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁴The Chinese University of Hong Kong, New Territories, China
Background/Purpose: Rheumatoid arthritis (RA) and systemic glucocorticoid (GC) use are associated with increased risk of cardiovascular disease. The latest RA management recommendations from the American…
Abstract Number: 2450 • ACR Convergence 2023
Gene by Respiratory Disease Interactions Associated with Developing Rheumatoid Arthritis
Vanessa Kronzer¹, Keigo Hayashi², Cynthia Crowson¹, John Davis¹, Gregory McDermott², Jing Cui³, Elena Losina³, Pierre-Antoine Juge⁴, James Cerhan¹ and Jeffrey Sparks⁵, ¹Mayo Clinic, Rochester, MN, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Cigarette smoking, textile dust, and occupational inhalants all strongly interact with the Human Leukocyte Antigen (HLA) shared epitope for risk of seropositive RA. Recently,…
Abstract Number: 2540 • ACR Convergence 2023
The Molecular Stratification of Rheumatoid Arthritis Using High-throughput Technologies Is Directly Associated with Disease Activity and Clinical Response
Ismael Sanchez-Pareja¹, Daniel Toro-Dominguez², Carlos Perez-Sanchez³, Laura Muñoz-Barrera¹, Tomás Cerdó¹, Rafaela Ortega Castro⁴, Jerusalem Calvo⁵, Marta Rojas⁶, Pilar Font Ugalde¹, Maria del Carmen Abalos-Aguilera⁷, Desiree Ruiz-Vilchez¹, Christian Merlo-Ruiz¹, Ivan Arias de la Rosa⁸, Mª Angeles Aguirre⁹, Eduardo Collantes Estévez¹⁰, Nuria Barbarroja¹¹, Marta Alarcon-Riquelme¹², Alejandro Escudero Contreras⁵ and Chary Lopez-Pedrera¹³, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ²GENYO, Granada, Spain, ³IMIBIC, Córdoba, Spain, ⁴Hospital Reina Sofía, Cordoba, Spain, ⁵Reina Sofia University Hospital, Córdoba, Spain, ⁶Hospital Universitario Reina Sofía, Cordoba, Spain, ⁷Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁸IMIBIC/Reina Sofia Hospital/University of Cordoba. Rheumatology service. Cordoba. Spain, Cordoba, Spain, ⁹Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ¹⁰Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, ¹¹University of Cordoba, Córdoba, Spain, ¹²Center for Genomics and Oncological Research (GENYO), Granada, Spain, ¹³IMIBIC - Reina Sofia Hospital, Córdoba, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a remarkably heterogeneous autoimmune disease whose clinical outcomes with disease-modifying antirheumatic drugs (DMARDs) remain unpredictable. The aim of this study…
Abstract Number: 0024 • ACR Convergence 2023
Detection of Synovial Signatures in Peripheral Blood of Patients with Rheumatoid Arthritis via a Novel Blood-Based DNA Capture Assay
Peter C. Taylor¹, Jenya Antonova², Jennifer Geis³, Katharine Dilger³, David Chernoff⁴, Diana Abdueva³, Nancy Shadick⁵ and Michael Weinblatt⁶, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Compass Strategy and Research, Inc., San Francisco, CA, ³Aqtual Inc., Hayward, CA, ⁴Chernoff Consulting, Sausalito, CA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Harvard Medical School, Waban, MA
Background/Purpose: In rheumatoid arthritis [RA], synovial biopsies were shown to guide therapy selection1. However, biopsies require special training for clinicians and are semi-invasive for patients.…
Abstract Number: 0086 • ACR Convergence 2023
Optimizing PD-1 Agonist Signaling with Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody
Stephen Parmley, Benjamin Szylyk, Richard Frank, Matthew Hsu, Polina Brodsky, Cailin Sibley, Paul Lizzul and Martin Dahl, AnaptysBio, San Diego, CA
Background/Purpose: Checkpoint antagonist therapeutics have transformed the field of oncology while advancing the understanding of adequate checkpoint activity in preventing autoimmunity. Checkpoint agonism represents a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].